XNAS
ACHL
Market cap60mUSD
Mar 20, Last price
1.48USD
Name
Achilles Therapeutics PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
136.30%
Rev. gr., 5y
%
Revenues
0k
Net income
-70m
L-2.12%
CFO
-48m
L-18.62%
Earnings
Aug 12, 2025
Profile
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 84,721 | 82,071 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (84,721) | (82,071) | ||||
NOPBT Margin | ||||||
Operating Taxes | 491 | 111 | ||||
Tax Rate | ||||||
NOPAT | (85,212) | (82,182) | ||||
Net income | (69,665) -2.12% | (71,176) 16.49% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 9 | 1,000 | ||||
BB yield | -0.03% | 0.00% | ||||
| Debt | ||||||
Debt current | 3,539 | 4,188 | ||||
Long-term debt | 5,691 | 12,964 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 1,015 | 933 | ||||
Net debt | (122,342) | (156,219) | ||||
| Cash flow | ||||||
Cash from operating activities | (48,449) | (59,535) | ||||
CAPEX | (1,100) | (7,512) | ||||
Cash from investing activities | (1,100) | (7,512) | ||||
Cash from financing activities | 9 | 1,000 | ||||
FCF | (69,475) | (79,506) | ||||
| Balance | ||||||
Cash | 131,539 | 173,338 | ||||
Long term investments | 33 | 33 | ||||
Excess cash | 131,572 | 173,371 | ||||
Stockholders' equity | (272,841) | (211,928) | ||||
Invested Capital | 420,840 | 418,155 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 39,973 | 39,140 | ||||
Price | 0.89 -1.22% | 0.90 -82.04% | ||||
Market cap | 35,536 0.88% | 35,226 -75.46% | ||||
EV | (86,806) | (120,993) | ||||
EBITDA | (80,008) | (78,381) | ||||
EV/EBITDA | 1.08 | 1.54 | ||||
Interest | 7,318 | |||||
Interest/NOPBT | ||||||